NOVALIQ GMBH

Their core work

NOVALIQ GmbH is a Heidelberg-based pharmaceutical company specialising in ophthalmic drug development, with a particular focus on diseases of the ocular surface such as dry eye disease and corneal disorders. Their practical contribution to research consortia lies in pharmaceutical formulation expertise and medicinal chemistry — translating biological insights into drug candidates and dosage forms suited for the eye. In the H2020 context they functioned as an industry partner bridging academic research and product development: hosting or co-supervising early-stage researchers in a Marie Curie training network and contributing clinical/formulation knowledge to a corneal regeneration programme. This positions them as a specialist industry node for anyone needing pharma-industry rigour in ophthalmology consortia.

What they specialise in

How they've shifted over time

NOVALIQ's earliest H2020 engagement (ARREST BLINDNESS, 2016) sat inside a broad regenerative medicine programme targeting corneal blindness — the keywords were generic and the company's specific formulation skills were not the focal theme. By 2018 their second project, IT-DED3, shows a sharper and more proprietary profile: dry eye disease, drug discovery, medicinal chemistry, and pharmaceutical formulation are all named explicitly, suggesting the company itself pushed for that specificity in the consortium description. The arc is not a pivot but a narrowing: from "ocular surface regeneration" broadly to "drug development for the anterior eye surface" specifically.

NOVALIQ is moving toward tighter, programme-specific drug development roles in the ocular surface space — future collaborations are most likely in ophthalmic drug delivery, phase-transitional formulation science, or industry-academic training programmes in eye disease.

How they like to work

NOVALIQ has not led any H2020 projects; in both cases they joined as participant or third-party partner, the typical profile of a specialist industry actor contributing proprietary expertise rather than coordinating large consortia. Despite the small project count, their network is relatively wide — 29 unique partners across 12 countries — which suggests they integrate well into large international consortia even when playing a focused supporting role. This makes them a practical choice as an industry anchor for academic-led consortia that need a credible pharmaceutical company on the team.

NOVALIQ has built connections with 29 partner organisations across 12 countries through just two projects, an unusually broad network for such a small project footprint, likely reflecting the large MSCA-ITN training consortium structure of IT-DED3. Their geographic reach is genuinely pan-European.

What sets them apart

NOVALIQ occupies a narrow but commercially credible niche: a non-SME private pharma company in Germany with documented ophthalmic drug formulation and medicinal chemistry skills, not a university spin-out but a company with product development orientation. For consortium builders in the eye disease or ophthalmic medtech space, this combination — industry seriousness, specific formulation knowhow, and an established MSCA training network track record — is hard to substitute with an academic partner alone. Their Heidelberg base also places them inside one of Germany's premier life-science clusters, giving informal access to a wider pharma ecosystem.

Highlights from their portfolio

• IT-DED3
  A Marie Curie Innovative Training Network dedicated entirely to dry eye disease drug development — rare in its specificity — where NOVALIQ's named role as industry partner signals direct commercial relevance to the research agenda.
• ARREST BLINDNESS
  A funded Health RIA (EUR 149,250 to NOVALIQ) on regenerative therapies for corneal blindness, demonstrating early access to large cross-disciplinary ophthalmology consortia beyond their dry eye niche.